临床路径工具对骨转移姑息放疗适宜性的影响
该研究在学术放疗机构设计并实施基于网络的骨转移放疗临床路径工具,评估其对单次放疗(SFRT)使用率的影响。路径包含20个终点和多个验证性预后评分系统,在723例骨转移放疗处方中使用率为38%,适宜SFRT率从实施前的18%升至实施后的48%(P < .01)。主要拒绝推荐的原因包括对预期寿命判断的分歧和患者便利性。
要点
- 临床路径工具使骨转移适宜SFRT率从18%提升至48%(P < .01)。
- 路径使用率为38%,主要拒绝原因为预后判断分歧和患者便利性。
- 路径提高了医生对指南依从性的信心并便于查找有依据的建议。
核心结论
- 临床路径决策支持在复杂学术环境中对骨转移放疗具有实用性。
研究设计与样本
- 研究在Dana Farber/Brigham and Women's Cancer Center主院区及附属社区站点开展,基于网络电子界面于2016年3月启动骨转移放疗临床路径。
- 路径基于已发表文献、临床指南和专家意见设计,包含20个终点和多个验证性预后评分系统。
- 对实施前后提供者进行问卷调查,评估路径使用率、SFRT推荐依从性及不依从原因。
主要发现
- 路径在723例骨转移放疗处方中使用率为38%。
- 适宜SFRT率从实施前的18%上升至实施后的48%(P < .01)。
- 拒绝推荐的主要原因包括对预期寿命判断的分歧和患者便利性。
- 路径增加了医生对治疗指南依从性的信心,并使查找有充分支持的治疗建议更容易。
- 工作流程中断和处理细微情况的能力不足成为局限性。
关键数值与推荐
- 指南推荐对无并发症骨转移的姑息治疗采用单次放疗(SFRT)。
临床怎么用
- 在学术放疗实践中可借助临床路径工具提高骨转移患者SFRT的适宜使用率。
- 需关注路径对工作流程的干扰及处理复杂临床情况的能力局限。
局限性
- 路径使用率仅为38%,可能影响效果的全面评估。
- 工作流程中断和无法处理细微情况是路径的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Clinical pathways increase compliance with treatment guidelines, improve outcomes, and reduce costs. Guidelines recommend single fraction radiation therapy (SFRT) for palliation of uncomplicated bone metastases, but implementation is variable. We examined the effects of a pathway tool on SFRT rates in an academic radiation oncology practice. METHODS AND MATERIALS: Using published literature, clinical guidelines, and expert input, we designed a clinical pathway for bone metastases radiation therapy displayed on a Web-based electronic interface. In March 2016, the pathway launched on a palliative radiation service at the Dana Farber/Brigham and Women's Cancer Center main campus and at affiliated community sites. Providers were surveyed pre- and postimplementation to assess expectations and elicit feedback. Rates of pathway utilization, compliance with SFRT recommendations, and reasons for noncompliance were assessed. RESULTS: The final pathway includes 20 endpoints and several validated prognostic scoring systems. It was used in 38% of 723 bone metastases radiation prescriptions, with appropriate SFRT rates rising from 18% before implementation to 48% after launch (P < .01). Major reasons for rejecting recommendations included disagreement with life expectancy prognostication and patient convenience. The pathway increased physicians' confidence regarding compliance with treatment guidelines and made it easier to find well-supported treatment recommendations. Workflow disruptions and the inability to handle nuanced situations emerged as limitations. CONCLUSIONS: Our experience demonstrates the utility of clinical pathway decision support for bone metastases radiation in complex academic settings. Next steps include increasing the pathway's ease of use, refining the pathway's prognostic abilities, and measuring cost savings related to the pathway.
引用
- Rotenstein LS, Kerman AO, Killoran J, et al. Impact of a clinical pathway tool on appropriate palliative radiation therapy for bone metastases. Pract Radiat Oncol. 2017. PMID: 29429920. doi:10.1016/j.prro.2017.12.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。